BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Iloperidone (Fanapt) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Iloperidone (Fanapt)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06961968-1732@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Iloperidone (Fanapt): Phase 3 readout est. (NCT06961968)
DESCRIPTION:Iloperidone (Fanapt)\, phase 3\, Schizophrenia.\nStudy: Randomi
 zed Withdrawal Study in Patients With Schizophrenia\nEstimated primary com
 pletion: November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/iloperidone-fanapt#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06961968
URL:https://assetmemo.bio/drug/iloperidone-fanapt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05648591-1732@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iloperidone (Fanapt): Phase 4 readout est. (NCT05648591)
DESCRIPTION:Iloperidone (Fanapt)\, phase 4\, Schizophrenia.\nStudy: Safety 
 and Tolerability of Open-Labeled Iloperidone in Adolescents\nEstimated pri
 mary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/iloperidone-fanapt#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05648591
URL:https://assetmemo.bio/drug/iloperidone-fanapt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
